Cue Biopharma (CUE) Total Debt (2022 - 2025)

Cue Biopharma has disclosed Total Debt across 4 years of filings, most recently posting $1.6 million for Q3 2025.

• Total Debt for Q3 2025 came in at $1.6 million, down 68.85% year-over-year; the trailing twelve-month figure through Sep 2025 was $1.6 million (down 68.85% YoY), and the FY2024 annual result was $4.3 million, down 46.93% from the prior year.
• Total Debt came in at $1.6 million for Q3 2025 at Cue Biopharma, down from $2.6 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $10.1 million in Q2 2023 to a low of $1.6 million in Q3 2025.
• The 4-year median for Total Debt is $8.2 million (2023), against an average of $7.2 million.
• Across the five-year window, Total Debt climbed 1.82% in 2023 and slumped 68.85% in 2025, its largest moves.
• Cue Biopharma's Total Debt stood at $10.0 million in 2022, then dropped by 18.33% to $8.2 million in 2023, then plunged by 46.93% to $4.3 million in 2024, then tumbled by 61.97% to $1.6 million in 2025.
• The last three Total Debt figures came in at $1.6 million (Q3 2025), $2.6 million (Q2 2025), and $3.4 million (Q1 2025), per Business Quant data.